Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial.

Pubmed ID: 35932912

Journal: American heart journal

Publication Date: Dec. 1, 2022

Affiliation: Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT. Electronic address: michael.nanna@yale.edu.

MeSH Terms: Humans, Hypertension, Treatment Outcome, Antihypertensive Agents, Chlorthalidone, Amlodipine, Lisinopril, Isolated Systolic Hypertension

Authors: Nanna MG, Wang SY, Hanna JM, Gongal P, Onuma OK

Cite As: Wang SY, Hanna JM, Gongal P, Onuma OK, Nanna MG. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial. Am Heart J 2022 Dec;254:30-34. Epub 2022 Aug 4.

Studies:

Abstract

Despite broad treatment recommendations, there are limited published reports comparing the efficacy of different antihypertensive agents in patients with isolated systolic hypertension or isolated diastolic hypertension. This study was a secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. We compared the use of chlorthalidone, amlodipine, or lisinopril on the primary outcome of combined coronary heart disease, stroke, or all-cause mortality in patients with isolated systolic hypertension or isolated diastolic hypertension.